IFNG and breast cancer: In contrast, inhibition of pY239/240ShcA-coupled signalling pathways in mammary tumours (MT/Shc2F/2F) specifically elicits immune surveillance in vivo (Fig. 1c,d and Supplementary Fig. 1), despite the fact that IFNγ-driven signalling responses are basally reduced in these cell lines in vitro (Fig. 2).